Effect of polymer molecular weight on the production of drug nanoparticles

Journal of Pharmaceutical Sciences

Volumn 96, Issue 10, 2007, Pages 2655-2666

  Sepassi, S ^a   Goodwin, D J ^a   Drake, A F ^a   Holland, S ^b   Leonard, G ^b   Martini, L ^b   Lawrence, M J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Colloid; Formulation; Nanoparticles; Physical characterization; Polymers

Indexed keywords

HALOFANTRINE; HYDROXYPROPYLMETHYLCELLULOSE; METHYLCELLULOSE; NABUMETONE; NANOPARTICLE; POLYMER; POVIDONE;

ABSORPTIOMETRY; ARTICLE; CONCENTRATION (PARAMETERS); DRUG COATING; DRUG MANUFACTURE; DRUG STABILITY; HYDROPHOBICITY; MOLECULAR WEIGHT; OPTICAL ROTATORY DISPERSION; PARTICLE SIZE; POLYMERIZATION; ULTRAVIOLET RADIATION; VISCOMETRY;

EID: 35349016405     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20979     Document Type: Article

References (36)

1. Atkinson RM, Bedford C, Child KJ, Tomich EG. 1962. Effect of particle size on blood griseofulvin levels in man. Nature 193:588-589.
2. Shaw TRD, Carless JE, Howard MR, Raymond K. 1973. Particle size and absorption of digoxin. Lancet 2:209-210.
3. Yakou S, Yamazaki S, Sonobe T, Sugihara M, Fukumuro K, Nagai T. 1986. Particle-size dependency of dissolution rate and human bioavailability of Phenytoin in powders and phenytoin polyethylene-glycol solid dispersions. Chem Pharm Bull 34:4400-4402.
4. Hargrove JT, Maxson WS, Wentz AC. 1989. Absorption of oral progesterone is influenced by vehicle and particle-size. Am J Obstet Gynecol 161:948-951.
5. Chaumeil JC. 1998. Micronization: A method of improving the bioavailability of poorly soluble drugs. Methods Find Exp Clin Pharmacol 20:211-215.
6. Müller RH, Becker R, Kruss B, Peters K. 1998. Pharmaceutical nanosuspension for medicament administration as system of increased saturation solubility and rate of solution. US Patent No. 5858410.
7. Liversidge GG, Cundy KC, Bishop JF, Czekai DA. 1992. Surface modified drug nanoparticles. US Patent No. 5145684.
8. Vasukumar K, Bansal A. 2003. Supercritical fluid technology in pharmaceutical research. CRIPS 4:8-12.
9. Merisko-Liversidge E, Liversidge GG, Cooper ER. 2003. Nanosizing: A formulation approach for poorly-water soluble compounds. Eur J Pharm Sci 18:113-120.
10. Liversidge GG, Conzentino P. 1995. Drug particle size reduction for decreasing irritancy and enhancing absorption of naproxen in rats. Int J Pharm 125:309-313.
11. Liversidge GG, Cundy KC. 1995. Particle size improvement of oral bioavailability of hydrophobic drugs I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 125:91-97.
12. Merisko-Liversidge E, McGurk SL, Liversidge GG. 2004. Insulin nanoparticles: A novel formulation approach for poorly water soluble Zn-insulin. Pharm Res 21:1545-1553.
13. Kipp JE. 2004. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm 284:109-122.
14. Ruddy SB, Roberts ME. 1998. Nanoparticles containing the R(-) enantiomer of ibuprofen. US Patent No. 5718919.
15. Kellaway IW, Najib NM. 1980. The adsorption of hydrophilic polymers at the polystyrene-water interface. Int J Pharm 6:285-294.
16. Tanaka R, Williams PA, Meadows J, Phillips GO. 1992. The adsorption of hydroxyethyl cellulose and hydrophobically modified hydroxyethyl cellulose onto polystyrene latex. Coll Surf 66:63-72.
17. Cosgrove T, Mears SJ, Obey T, Thompson L, Wesley RD. 1999. Polymer, particle, surfactant interactions. Coll Surf A 149:329-338.
18. Law SL, Kayes JB. 1983. Adsorption of non-ionic water-soluble cellulose polymers at the solid-water interface and their effect on suspension stability. Int J Pharm 15:251-260.
19. Duro R, Alvarez C, Martinez-Pacheco R, Gomez-Amoza JL, Concheiro A, Souto C. 1998. The adsorption of cellulose ethers in aqueous suspensions of pyrantel pamoate: Effects on zeta potential and stability. Eur J Pharm Biopharm 45:181-188.
20. Lee J. 2003. Drug nano- and microparticles processes into solid dosage forms: Physical properties. J Pharm Sci 92:2057-2068.
21. British Pharmacopoeia2005. London: Her Majesty's Stationary Office.
22. Büler V, Klodwig U. 1984. Characterizing the molecular weight of polyvinylpyrrolidone. Acta Pharm Tech 30:317-324.
23. Sultana S. 2000. Comparision between polyvinylpyrrolidone-based and polyoxazoline non-ionic surfactants: Their physico-chemical and solubilisation behaviour PhD Thesis London University.
24. Rawle A. 2002. The advances in particle sizing to the coatings industry part 1: Particle size measurement. Adv Col Sci Tech 5:1-12.
25. Date AD, Patravale VB. 2004. Current strategies for engineering drug nanoparticles. Curr Opin Coll Int Sci 9:222-235.
26. Parrott EL. 1974. Milling of Pharmaceutical Solids. J Pharm Sci 63:813-829.
27. Denison B. 1990. Bead milling - A practical guide. J Oil Col Chem Assoc 6:256-261.
28. Yokoyama T, Tamura H, Usui H, Jimbo G. 1996. Simulation of ball behaviour in a vibration mill in relation with its grinding rate: Effects of fractional ball filling and liquid viscosity. Int J Miner Process 44-45:413-424.
29. Lochhead RY. 1992. Water soluble polymers solution adsorption and interaction characteristics. Cosmet Toiletries 107:131-156.
30. Sato T. 1993. Stability of dispersion. J Coating Technol 65:113-120.
31. Fleer GJ, Cohen Stuart MA, Scheutjens JMHM, Cosgrove T, Vincent B. 1993. Polymers at Interfaces. London: Chapman and Hall.
32. Büler V. 1996. Kollidon: Polyvinylpyrrolidone for the Pharmaceutical Industry Ludwigshafen: BASF.
33. United States Pharmacopoeia 231995. US Pharmacopoeial Convention, Rockville, MD.
34. Radeva T. 2002. Adsorption of polymer at colloid surfaces. In: Hubbard A, editor. Encyclopedia of Surface and Colloid Science. New York: Marcel Dekker. p 547-557.
35. Sawyer CB, Reed JS. 2001. Adsorption of hydroxypropyl methyl cellulose in an aqueous system containing multicomponent oxide particles. J Am Ceram Soc 84:1241-1249.
36. Molyneux P. 1983. Water-Soluble Synthetic Polymers: Properties and Behaviour. Volume II. Florida: CRC Press.